middl
east
respiratori
syndrom
coronaviru
merscov
continu
spread
caus
sever
fatal
acut
respiratori
diseas
human
prophylact
therapeut
strategi
therefor
urgent
need
control
merscov
infect
gener
human
monoclon
antibodi
mab
design
target
merscov
receptorbind
domain
rbd
high
affin
significantli
block
merscov
rbd
bind
viral
receptor
human
dipeptidyl
peptidas
potent
neutral
infect
prototyp
merscov
effect
crossneutr
evolv
merscov
isol
recogn
highli
conserv
rbd
epitop
notabl
singledos
treatment
complet
protect
transgen
mice
lethal
infect
merscov
taken
togeth
data
suggest
might
develop
effect
immunotherapeut
agent
treat
patient
infect
merscov
particularli
emerg
case
middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
saudi
arabian
patient
septemb
zaki
et
al
caus
human
infect
part
world
thu
becom
global
concern
particular
outbreak
south
korea
result
infect
death
http
march
total
laboratoryconfirm
case
includ
death
report
http
wwwwhointemergenciesmerscov
en
repres
mortal
rate
symptom
caus
merscov
similar
sever
acut
respiratori
syndrom
coronaviru
sarscov
relat
coronaviru
fatal
rate
led
epidem
skowronski
et
al
zhong
et
al
unlik
sarscov
addit
case
report
sinc
du
et
al
merscov
shown
continu
increas
number
case
particularli
saudi
arabia
suggest
potenti
futur
epidem
statu
nevertheless
clinic
approv
vaccin
antivir
therapeut
current
avail
highlight
urgent
need
potent
strategi
combat
viru
merscov
belong
betacoronaviru
genu
coronaviru
famili
de
groot
et
al
zaki
et
al
spike
protein
consist
subunit
play
import
role
viral
entri
host
cell
bonavia
et
al
gao
et
al
xu
et
al
merscov
depend
receptorbind
domain
rbd
subunit
bind
viral
receptor
human
dipeptidyl
peptidas
host
cell
surfac
follow
subunit
undergo
dramat
conform
chang
allow
membran
fusion
subsequ
merscov
penetr
cellular
membran
lu
et
al
raj
et
al
wang
et
al
therefor
entri
merscov
target
cell
might
prevent
either
block
viral
receptor
bind
inhibit
merscovhost
cell
membran
fusion
vaccin
passiv
therapeut
effect
approach
viral
infect
gener
vaccin
provid
immedi
prophylact
protect
treatment
ongo
viral
infect
comparison
passiv
therapeut
base
neutral
monoclon
antibodi
mab
emerg
power
tool
provid
prophylact
therapeut
protect
viral
infect
du
et
al
zhu
et
al
sever
human
human
viralneutr
mab
develop
almost
target
rbd
corti
et
al
jiang
et
al
li
et
al
pascal
et
al
tang
et
al
ying
et
al
yu
et
al
suggest
merscov
rbd
repres
ideal
target
neutral
mab
develop
previous
develop
murin
mab
target
merscov
rbd
potent
neutral
merscov
infect
human
gener
human
mab
exhibit
high
affin
rbd
bind
first
investig
activ
well
mechan
neutral
merscov
cell
entri
second
evalu
abil
neutral
emerg
merscov
strain
final
demonstr
singledos
treatment
abl
elicit
full
protect
lethal
merscov
infect
transgen
mous
model
note
repres
first
mab
report
exhibit
capac
protect
treat
anim
lethal
infect
merscov
anim
studi
perform
strict
accord
recommend
guid
care
use
laboratori
anim
anim
protocol
approv
iacuc
laboratori
anim
center
state
key
laboratori
pathogen
biosecur
beij
institut
microbiolog
epidemiolog
permit
number
bime
procedur
involv
merscov
carri
approv
biosafeti
level
facil
merscov
rbd
protein
prepar
previous
describ
et
al
briefli
merscov
rbd
genbank
access
residu
spike
protein
fuse
ctermin
human
fc
tag
transient
express
cell
cultur
system
purifi
use
hitrap
protein
ff
fcfuse
protein
histrap
hp
tag
protein
ge
healthcar
littl
chalfont
uk
mutant
rbd
protein
gener
sitespecif
polymeras
chain
reaction
pcr
mutagenesi
confirm
sequenc
analysi
mutant
rbd
contain
ctermin
tag
transient
express
cell
supernat
purifi
histrap
hp
describ
mab
gener
human
murin
mab
use
previous
describ
protocol
bouliann
et
al
briefli
total
rna
isol
hybridoma
cell
use
synthes
cdna
primer
mvhf
atg
gra
tgg
agc
tgg
atc
tt
mvhr
ata
gac
aga
tgg
ggg
tgt
cgt
ttt
ggc
use
amplifi
variabl
region
heavi
chain
v
h
gene
mvkf
atg
gagwca
gac
aca
ctc
ct
mvkr
gga
taca
gtt
ggt
gca
gca
tc
du
et
al
use
variabl
region
light
chain
v
l
gene
sequenceconfirm
v
h
v
l
gene
insert
prboig
express
vector
contain
human
human
immunoglobulin
kappa
chain
constant
region
recombin
plasmid
transfect
cell
human
mab
purifi
cell
cultur
supernat
purifi
mab
resolv
reduc
sodium
dodecyl
sulphatepolyacrylamid
electrophoresi
sdspage
nonreduc
sdspage
respect
reactiv
merscov
rbd
detect
elisa
describ
briefli
elisa
plate
coat
overnight
tag
rbd
protein
block
nofat
milk
h
serial
dilut
trastuzumab
control
roch
roswel
ga
usa
ad
plate
incub
h
horseradish
peroxidaseconjug
goat
antihuman
igg
santa
cruz
biotechnolog
dalla
tx
usa
ad
incub
h
reaction
visual
tmb
substrat
addit
invitrogen
carlsbad
ca
usa
stop
h
absorb
nm
measur
use
elisa
plate
reader
biotek
winooski
vt
usa
halfmaxim
effect
concentr
ec
calcul
use
graphpad
prism
softwar
la
jolla
ca
usa
epitop
map
perform
elisa
describ
except
elisa
plate
coat
seri
mutant
rbd
protein
affin
bind
merscov
rbd
assay
use
biacor
instrument
ge
healthcar
littl
chalfont
uk
immobil
sensor
chip
amin
coupl
kit
refer
flow
cell
treat
amin
coupl
reagent
without
exposur
run
buffer
hbsep
mm
hepe
ph
mm
nacl
mm
edta
surfact
tag
rbd
protein
gradient
concentr
nm
flow
chip
surfac
chip
regener
mm
h
po
sensorgram
analyz
use
biaevalu
softwar
data
fit
bind
model
merscov
neutral
assay
perform
describ
du
et
al
tao
et
al
briefli
serial
trastuzumab
control
incub
tissu
cultur
infect
dose
tcid
merscov
h
follow
incub
vero
cell
h
cytopath
effect
cpe
observ
daili
record
day
follow
inocul
neutral
dose
nd
calcul
reedmuench
method
reed
muench
determin
antibodi
concentr
complet
inhibit
virusinduc
cpe
least
well
determin
inhibitori
abil
bind
merscov
rbd
cell
perform
flow
cytometri
describ
du
et
al
briefli
cell
incub
fcfuse
rbd
protein
presenc
serial
dilut
trastuzumab
control
room
temperatur
min
follow
incub
dylight
goat
antihuman
igg
antibodi
room
temperatur
min
fluoresc
signal
analyz
flow
cytometri
guava
emd
millipor
germani
pseudoviru
neutral
assay
perform
describ
briefli
cell
cotransfect
plasmid
encod
envdefect
luciferaseexpress
genom
encod
merscov
spike
protein
strain
merscov
emerg
strain
correspond
rbd
mutat
packag
pseudotyp
merscov
pseudovirus
incub
serial
dilut
h
mixtur
ad
cell
preplat
tissu
cultur
plate
well
h
inocul
h
cell
lyse
cell
lysi
buffer
promega
madison
wi
usa
transfer
luminomet
plate
luciferas
activ
determin
use
infinit
luminomet
tecan
san
jose
ca
usa
nd
calcul
use
doserespons
inhibit
model
graphpad
prism
total
fulllength
spike
protein
sequenc
collect
mer
coronaviru
databas
viru
variat
resourc
brister
et
al
multipl
sequenc
align
use
muscl
program
edgar
genbank
access
number
select
merscov
isol
list
supplementari
materi
method
use
femal
mice
evalu
passiv
therapeut
effect
lethal
merscov
infect
follow
intraperiton
anesthet
sodium
pentobarbit
mgkg
bodi
weight
mice
lethal
viru
infect
intranas
inocul
tcid
merscov
strain
dulbecco
modifi
eagl
medium
dmem
h
mice
intraven
inject
mgkg
purifi
trastuzumab
mab
control
infect
mice
observ
day
calcul
bodi
weight
chang
surviv
rate
addit
mice
sacrif
group
day
postinfect
lung
tissu
collect
virolog
detect
histopatholog
evalu
viral
titer
detect
describ
briefli
mous
lung
tissu
homogen
dmem
plu
antibiot
achiev
wv
suspens
titrat
monolay
vero
cell
quadrupl
cpe
observ
daili
phasecontrast
microscopi
day
viral
titer
calcul
reedmuench
method
express
log
tcid
g
tissu
collect
tissu
immedi
fix
neutral
buffer
formalin
embed
paraffin
section
thick
gener
mount
onto
slide
stain
hematoxylin
eosin
h
e
histopatholog
chang
observ
use
light
microscopi
extent
lung
injuri
score
accord
level
degener
necrosi
bronchi
bronchiolar
epithelium
infiltr
inflammatori
cell
alveoli
degener
collaps
expans
parenchym
wall
hemorrhag
interstiti
edema
sun
et
al
statist
analys
perform
use
graphpad
prism
version
signific
surviv
curv
analyz
kaplanmei
surviv
analysi
logrank
test
data
analyz
use
unpair
ttest
welch
correct
p
consid
signific
human
mab
express
cell
purifi
hitrap
protein
ff
reduc
nonreduc
sdspage
show
migrat
singl
protein
approxim
kda
dissoci
heavi
light
chain
kda
reduc
condit
fig
b
accord
characterist
human
antibodi
reactiv
merscov
rbd
subsequ
measur
elisa
shown
tabl
maintain
abil
parent
mab
react
strongli
merscov
rbd
ec
compar
trastuzumab
control
react
rbd
data
shown
interact
merscov
rbd
also
character
spr
show
k
pm
result
suggest
human
mab
success
gener
exhibit
high
affin
merscov
rbd
bind
neutral
activ
live
merscov
infect
determin
could
potent
neutral
infect
live
merscov
strain
permiss
vero
cell
nd
tabl
wherea
trastuzumab
exhibit
antivir
activ
merscov
infect
result
suggest
human
maintain
potent
abil
neutral
merscov
infect
sinc
target
merscov
rbd
neutral
mechan
thu
investig
measur
abil
block
bind
merscov
rbd
receptor
flow
cytometr
analysi
wherea
high
fluoresc
intens
detect
cell
incub
rbd
protein
alon
background
fluoresc
level
observ
bind
sampl
presenc
suggest
abl
strongli
block
bind
merscov
rbd
cellassoci
fig
block
effect
occur
dosedepend
manner
fig
contrast
trastuzumab
affect
merscov
rbd
bind
cell
fig
b
result
strongli
suggest
neutral
merscov
infect
inhibit
bind
merscov
rbd
identifi
epitop
merscov
rbd
recogn
util
panel
mutant
rbd
protein
gener
mutat
key
residu
merscov
rbd
bind
interfac
alanin
bind
respect
mutant
rbd
protein
measur
elisa
describ
lu
et
al
capabl
recogn
rbd
mutant
reduc
bind
rbd
mutat
respect
fig
comparison
remain
mutat
rbd
affect
bind
rbd
except
exhibit
slight
loss
bind
activ
pseudoviru
neutral
assay
reveal
pseudotyp
merscov
express
spike
protein
contain
mutant
complet
abolish
reduc
inhibitori
effect
pseudoviru
infect
contrast
chang
abil
inhibit
mer
pseudoviru
infect
fig
result
indic
residu
rbd
crucial
neutral
epitop
recogn
align
fulllength
spike
protein
sequenc
deposit
ncbi
merscov
databas
illustr
rbd
epitop
recogn
highli
conserv
among
merscov
emerg
isol
supplementari
fig
particular
residu
natur
mutat
merscov
evolut
indic
abil
crossneutr
merscov
emerg
strain
understand
whether
natur
rbd
mutat
evolv
strain
merscov
isol
outbreak
affect
neutral
activ
construct
seri
pseudovirus
express
merscov
spike
protein
mutat
rbd
residu
exhibit
potent
neutral
activ
toward
mer
mutant
pseudovirus
test
nd
valu
rang
tabl
result
suggest
exhibit
abil
crossneutr
emerg
merscov
isol
wildtyp
mice
permiss
merscov
infect
coleman
et
al
passiv
immunotherapeut
effect
evalu
mous
model
merscov
infect
lead
fatal
outcom
h
follow
lethal
infect
merscov
tcid
mice
intraven
inject
singledos
mgkg
trastuzumab
mab
control
viral
titer
histopatholog
chang
bodi
weight
chang
surviv
rate
calcul
viral
titer
measur
mous
lung
three
day
follow
viral
infect
demonstr
mice
receiv
treatment
exhibit
significantli
lower
viral
titer
receiv
trastuzumab
mab
control
p
fig
suggest
inhibit
merscov
infect
vivo
examin
associ
histopatholog
chang
illustr
treatment
significantli
allevi
lung
injuri
induc
merscov
infect
p
fig
mice
lethal
merscov
infect
exhibit
fewer
histopatholog
chang
fig
accompani
small
degre
inflammatori
cell
infiltr
lung
interstiti
tissu
fig
f
contrast
sever
lung
damag
observ
control
mice
fig
develop
mark
interstiti
pneumonia
focal
exud
fig
macrophag
infiltr
fig
hemorrhag
fig
alveolar
septal
thicken
fig
j
addit
mice
exhibit
slight
decreas
bodi
weight
day
follow
subsequ
recoveri
wherea
control
mice
demonstr
dramat
bodi
weight
loss
fig
notabl
mice
surviv
lethal
merscov
infect
wherea
control
group
anim
die
day
postinfect
p
fig
result
confirm
singledos
mab
treatment
abl
complet
protect
mice
lethal
merscov
infect
merscov
infect
human
high
associ
mortal
pose
larg
threat
public
health
reinforc
urgenc
develop
effect
vaccin
therapeut
number
therapeut
mab
appli
clinic
prevent
treat
viral
infect
murray
et
al
qiu
et
al
suggest
neutral
mab
might
repres
promis
approach
combat
merscov
infect
well
merscov
rbd
elicit
strong
neutral
antibodi
respons
contain
critic
neutral
domain
et
al
zhang
et
al
thu
repres
ideal
target
neutral
mab
develop
notabl
almost
report
merscov
neutral
mab
includ
murin
human
human
mab
target
rbd
corti
et
al
du
et
al
li
et
al
pascal
et
al
tang
et
al
ying
et
al
yu
et
al
previous
develop
rbdtarget
murin
neutral
mab
demonstr
abil
neutral
merscov
infect
human
mab
evalu
bind
affin
rbd
inhibitori
abil
bind
neutral
crossneutr
activ
diverg
merscov
strain
isol
outbreak
therapeut
potenti
human
mab
also
investig
mice
data
clearli
show
human
mab
maintain
strong
reactiv
rbd
significantli
block
receptor
bind
potent
neutral
merscov
infect
demonstr
merscov
underw
evolut
outbreak
cotten
et
al
sabir
et
al
evalu
crossneutr
activ
merscov
emerg
strain
recogn
three
key
residu
neutral
epitop
merscov
rbd
highli
conserv
merscov
evolut
lead
hypothesi
might
effect
combat
infect
differ
merscov
emerg
isol
notabl
could
potent
neutral
seri
pseudovirus
express
spike
protein
merscov
isol
outbreak
differ
region
includ
saudi
arabia
south
korea
period
demonstr
crossneutr
activ
merscov
spread
evolut
sever
neutral
mab
includ
test
vivo
protect
efficaci
use
nonleth
merscov
challeng
mous
rabbit
model
corti
et
al
li
et
al
pascal
et
al
houser
et
al
studi
evalu
protect
efficaci
lethal
mous
model
wherein
demonstr
singledos
mgkg
complet
protect
mice
lethal
challeng
merscov
studi
therefor
suggest
might
develop
potent
passiv
therapeut
agent
treat
patient
infect
merscov
refer
web
version
pubm
central
supplementari
materi
work
support
china
nation
program
infecti
diseas
fund
nih
grant
intramur
fund
new
york
blood
center
tabl
characterist
human
mab
bind
kinet
merscov
rbd
measur
biacor
b
rbdspecif
reactiv
ec
determin
elisa
tabl
crossneutr
activ
pseudotyp
merscov
mutant
c
pseudotyp
merscov
express
spike
protein
strain
consid
prototyp
pseudoviru
nd
determin
use
pseudotyp
merscovbas
neutral
assay
